42-year-old woman in her 30th week of pregnancy who had undergone a mitral valve replacement with a 29-mm St. Jude Medical mechanical prosthetic valve (St. Jude Medical, St. Paul, Minn) 2 years earlier was referred to our hospital with severe dyspnea. She had a history of irregular and subtherapeutic use of enoxaparin 6000 IU/d until admission. Transthoracic echocardiography revealed a mean diastolic mitral transvalvular gradient of 29 mm Hg, mitral valve area of 0.6 cm 2 , and a giant thrombus with mobile components on the prosthetic valve ( Figure 1 ; online-only Data Supplement Movie I). In spite of the large prosthetic mitral valve thrombosis, she had no history of thromboembolism. Two-dimensional transesophageal echocardiography revealed an unprecedentedly large thrombus (6 cm 2 in area) appended to the mitral valve that was restricting the movement of 1 of the leaflets (Figure 2 Prosthetic heart valve thrombosis in pregnancy is a lifethreatening complication for which management remains controversial. Although review of the literature for management of prosthetic valve thrombosis in a pregnant patient reveals no set guidelines, thrombolytic therapy, thrombectomy, and prosthetic valve replacement are the currently available options. Surgery is usually favored in the current guidelines 1 for the management of obstructive prosthetic valve thrombosis; however, the reported operative mortality, depending on the functional class, can be as high as 69%. 2 We have reported previously that the high success rate of thrombolysis performed under 2-dimensional transesophageal echocardiographic guidance is independent of valve location and type, morphological characteristics of the prosthetic valve thrombi, and New York Heart Association class at presentation. 3 We have also recently shown that a low-dose, slow infusion of tissue plasminogen activator given in discrete successive sessions guided by serial 2-dimensional transesophageal echocardiography is associated with a low risk of complications and a high rate of success even in patients with obstructive thrombosis and New York Heart Association class III or IV. 4 
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